Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled study of VGX-3100 DNA vaccine with electroporation for CIN 2/3 associated with HPV16 or HPV18
KCT0000284Phase 2Withdrawn
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Dec 2011
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bizalimogene ralaplasmid in cervical intraepithelial neoplasia (CIN), HPV16 infection (HPV16), human papillomavirus infection, sponsored by Inovio Pharmaceuticals, Inc.. Planned start Dec 2011; status: withdrawn.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
cervical intraepithelial neoplasia (CIN)HPV16 infection (HPV16)human papillomavirus infection
Beyond the preview
Go deeper on KCT0000284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000284.